



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/395082/2019

European Medicines Agency decision P/0261/2019

of 16 July 2019

on the acceptance of a modification of an agreed paediatric investigation plan for ixazomib (Ninlaro) (EMA-001410-PIP02-17-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



European Medicines Agency decision

P/0261/2019

of 16 July 2019

on the acceptance of a modification of an agreed paediatric investigation plan for ixazomib (Ninlaro) (EMA-001410-PIP02-17-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0125/2018 issued on 11 April 2018 and the decision P/0376/2018 issued on 7 December 2018,

Having regard to the application submitted by Takeda Pharm A/S on 25 March 2019 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 June 2019, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for ixazomib (Ninlaro), powder for solution for injection, capsule, hard, intravenous use, oral use, gastric use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Takeda Pharm A/S, Dybendal Ale 10, 2630 – Taastrup, Denmark.

EMA/PDCO/218638/2019
Amsterdam, 28 June 2019

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001410-PIP02-17-M02

Scope of the application

Active substance(s):

Ixazomib

Invented name:

Ninlaro

Condition(s):

Treatment of multiple myeloma

Treatment of lymphoid malignancies (excluding multiple myeloma)

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Powder for solution for injection

Capsule, hard

Route(s) of administration:

Intravenous use

Oral use

Gastric use

Name/corporate name of the PIP applicant:

Takeda Pharm A/S

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Takeda Pharm A/S submitted to the European Medicines Agency on 25 March 2019 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0125/2018 issued on 11 April 2018 and the decision P/0376/2018 issued on 7 December 2018.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 30 April 2019.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of multiple myeloma

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- powder for solution for injection, capsule, hard, intravenous use, oral use, gastric use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subsets.

2. Paediatric investigation plan

2.1. Condition

Treatment of lymphoid malignancies (excluding multiple myeloma)

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients from birth to less than 18 years of age with a lymphoid malignancy

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for solution for injection

Capsule, hard

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Compatibility of ixazomib powder for solution for injection, oral use, gastric use, with flavouring agents or food and with naso-gastric feeding tubes. Generation of data on acceptability and palatability
Non-clinical studies	0	Not applicable

Clinical studies	5	Study 2 Uncontrolled, open label study to assess pharmacokinetics and safety of ixazomib capsules for oral use, and of powder for solution for injection, oral use and gastric use, in paediatric patients from birth to less than 18 years of age (and adults if diagnosed at less than 18 years of age) with relapsed/refractory acute lymphoblastic leukaemia or lymphoblastic lymphoma with or without extramedullary disease Study 3 Uncontrolled, open label study to assess pharmacokinetics and safety of ixazomib powder for solution for injection, intravenous use, in paediatric patients from birth to less than 18 years of age (and adults if diagnosed at less than 18 years of age) with relapsed/refractory acute lymphoblastic leukaemia or lymphoblastic lymphoma with or without extramedullary disease Study 4 Open-label, single arm study to assess the efficacy of the addition of ixazomib, capsules for oral use, and powder for solution for injection, oral use and gastric use, to reinduction chemotherapy in paediatric patients from birth to less than 18 years of age (and adults if diagnosed at less than 18 years of age) with relapsed/refractory (RR) acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LLy) with or without extramedullary disease Study 5 Randomised, controlled, open-label study to assess event free survival (EFS) of patients from birth to less than 18 years of age (and adults if diagnosed at less than 18 years of age) with relapsed or refractory (RR) acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LLy) with or without extramedullary disease treated with ixazomib in combination with vincristine, dexamethasone, L-asparaginase, and doxorubicin (VXLD) chemotherapy versus VXLD chemotherapy alone Study 6 Randomized, controlled study of modified augmented Berlin-Frankfurt-Münster (ABFM) regimen with bortezomib during induction/consolidation and intensification followed by maintenance therapy with/without ixazomib in patients from birth to less than 18 years of age (and adults if diagnosed at less than 18 years of age) with newly diagnosed ALL or LLy with or without extramedullary disease
Extrapolation, modelling and simulation studies	0	Not applicable

Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2031
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

Treatment of multiple myeloma

Authorised indication:

- Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

Authorised pharmaceutical form(s):

Hard capsule

Authorised route(s) of administration:

Oral use